RT Journal Article
SR Electronic
T1 Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.11.23284137
DO 10.1101/2023.01.11.23284137
A1 Tamandjou, Cynthia
A1 Auvigne, Vincent
A1 Schaeffer, Justine
A1 Vaux, Sophie
A1 du Châtelet, Isabelle Parent
YR 2023
UL http://medrxiv.org/content/early/2023/02/07/2023.01.11.23284137.abstract
AB In face of evidence of rapid waning of vaccine effectiveness against Omicron and its sub-lineages, a second booster with mRNA vaccines was recommended for the most vulnerable in France. We used a test negative design to estimate the effectiveness of the second booster relative to the first booster and the protection conferred by a previous SARS-CoV-2 infection, against symptomatic Omicron BA.2 or BA.4/5. We included symptomatic ≥60 years old individuals tested for SARS-CoV-2 in March 21-October 30, 2022. Compared to a 181-210 days old first booster, a second booster restored protection with a relative effectiveness of 39% [95%CI: 38% - 41%], 7-30 days post-vaccination This gain in protection was lower than the one observed with the first booster, at equal time points since vaccination. High levels of protection were associated to previous SARS-CoV-2 infection, especially if the infection was recent and occurred when an antigenic-related variant was dominant.HighlightsA second Wuhan-like mRNA booster brought additional protection against symptomatic Omicron BA.2 or BA.4/5 infections, relative to a first booster given 181 to 210 days ago.The gain in protection offered by a second booster was lower to the protection observed with a first booster, at equal time points since these booster doses.Previous infection, in a vaccinated population, offered high levels and long-lasting protection against symptomatic Omicron BA.2 or BA.4/5 infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This processing of personal pseudonymised data was implemented in accordance with the legislative and regulatory prerogatives granted to Sante publique France to fulfil its public interest mission and in compliance with the provisions of the GDPR. In this context, the Data Protection Officer of Sante Publique France specified that the opinion of an ethics committee was not required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhile all data used in this analysis were pseudonymised, the individual-level nature of the data used risks individuals being identified, or being able to self-identify, if it is released publicly. Requests for access to the underlying source data should be directed to Sante publique France and will be granted in accordance with the GDPR and French Law.